Showing 6421-6430 of 6983 results for "".
- Antiperspirant, Deodorant Use Disrupts Microbiomehttps://practicaldermatology.com/news/antiperspirant-deodorant-use-disrupts-microbiome/2458718/Wearing antiperspirant or deodorant may influence the type and quantity of bacterial life found in the armpit's microbiome, new research suggests. "Using antiperspirant and deodorant completely rearranges the microbial ecosystem of your skin -- what's
- Alastin SkinCare Appoints Lynn Salo to Board of Directorshttps://practicaldermatology.com/news/alastin-skincare-appoints-linda-salo-to-board-of-directors/2458719/Lynn Salo is now a member of ALASTIN™ Skincare, Inc.’s board of directors. Ms. Salo has 27 years of experience with Allergan in the U.S., Canada, and Europe, including her role as Vice President, Sales and Marketing for the Facial Aesthetic
- Survey: When it Come to Facial Aging Concerns, It's Like Mother, Like Daughterhttps://practicaldermatology.com/news/survey-when-it-come-to-facial-aging-concerns-its-like-mother-like-daughter/2458720/Galderma’s latest campaign Mom Genes™ aims to change the way moms and daughters talk about and approach facial aging. Fully 82 percent of moms hope facial aging is easier for their daughters, but more than half never talk about it togethe
- Take That, Zika! New Wearable Device Protects Against Mosquitoes that Transmit Zikahttps://practicaldermatology.com/news/take-that-zika-new-wearable-device-protects-against-mosquitoes-that-transmit-zika/2458722/OFF!® Clip-On™ repellent device may help keep Zika-carrying mosquitoes at bay, according to an article in the Journal of Medical Entomol
- Bristol-Myers Squibb Foundation Awards 8 Grants to Make Skin and Lung Cancer Screening More Accessible in High-Risk U.S. Communitieshttps://practicaldermatology.com/news/bristol-myers-squibb-foundation-awards-8-grants-to-make-skin-and-lung-cancer-screening-more-accessible-in-high-risk-us-communities/2458721/Bristol-Myers Squibb Foundation awarded eight grants totaling nearly $11.5 million to help make skin and lung cancer screening programs, care and patient support more accessible to underserved populations. The grants we
- FDA Issues Consumer Warning about Crema Piel De Seda (Silky Skin Cream) by Viansilk: Risk of Mercury Poisoninghttps://practicaldermatology.com/news/fda-issues-consumer-warning-about-crema-piel-de-seda-silky-skin-cream-by-viansilk-risk-of-mercury-poisoning/2458725/The FDA warned consumers not to purchase or use a skin whitening cream called “Crema Piel De Seda,” due to the risk of mercury poisoning. FDA laboratory analysis identified mercury in the product. Exposure to mercury can cause serious health problems, such as kidney and nervous system
- Surgical Specialties Corporation Acquires FSSB Chirurgische Nadein GMBHhttps://practicaldermatology.com/news/surgical-specialties-corporation-acquires-fssb-chirurgische-nadein-gmbh/2458735/Surgical Specialties Corporation has acquired all shares of FSSB Chirurgische Nadein GMBH (FSSB) and affiliated entities. Terms were not disclosed. The acquisition will be immediately accretive to both Surgical Specialties' sales and adjusted EBITDA. FSSB was founded in 1995 by c
- Review Article Shines Spotlight on Neurocutaneous Disordershttps://practicaldermatology.com/news/review-article-shines-spotlight-on-neurocutaneous-disorders/2458739/There are at least 60 genetic neurocutaneous disorders that involve the skin, central nervous system, according to a review article in the Current Neurology and Neuroscience Reports. For example, neurofibrom
- DERMAFLASH® Brings Benefits of Dermaplaning Homehttps://practicaldermatology.com/news/dermaflash-brings-benefits-of-dermaplaning-home/2458738/DERMAFLASH™ is the newest addition to the DIY beauty device market. Designed specifically for women, the noninvasive exfoliation device is based on the principles of dermaplaning. DERMAFLASH uses sonic vibration to sweep away dead skin cells, vellus and even coarser
- FDA Approves Updated Label for New Dosing Regimen for Allergan's Dalvancehttps://practicaldermatology.com/news/fda-approves-updated-label-for-new-dosing-regimen-for-allergans-dalvance/2458741/The FDA has approved Allergan plc’s supplemental new drug application (sNDA) to update the label for Dalvance® (dalbavancin) for injection. The expanded label will include a single dose administered as a 30-minute intravenous (IV) infusion of Dalvance for the treatment o